Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Total Liabilities (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Total Liabilities over the past 15 years, most recently at $191.9 million for Q2 2025.

  • For Q2 2025, Total Liabilities fell 4.07% year-over-year to $191.9 million; the TTM value through May 2025 reached $191.9 million, down 4.07%, while the annual FY2025 figure was $191.9 million, 4.07% down from the prior year.
  • Total Liabilities for Q2 2025 was $191.9 million at Lifecore Biomedical, Inc. \De\, up from $190.3 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $304.7 million in Q1 2021 and troughed at $163.1 million in Q1 2023.
  • A 5-year average of $214.4 million and a median of $201.8 million in 2023 define the central range for Total Liabilities.
  • Biggest five-year swings in Total Liabilities: crashed 40.36% in 2022 and later grew 16.9% in 2023.
  • Year by year, Total Liabilities stood at $265.9 million in 2021, then dropped by 22.96% to $204.8 million in 2022, then decreased by 0.66% to $203.5 million in 2023, then dropped by 3.86% to $195.6 million in 2024, then fell by 1.9% to $191.9 million in 2025.
  • Business Quant data shows Total Liabilities for LFCR at $191.9 million in Q2 2025, $190.3 million in Q1 2025, and $195.6 million in Q4 2024.